Patent · US Active

Compounds that are ERK inhibitors

US9023865B2 · kind B2 · utility

2Cited by

0References

20Claims

0Family size

Assignee

Merck Sharp & Dohme LLC · US

Inventors

Jongwon Lim · Lexington, US
Elizabeth H. Kelley · Cambridge, US
Joey L. Methot · Westwood, US
Hua Zhou · Acton, US
Alessia Petrocchi · Roma, IT
Umar Faruk Mansoor · Framingham, US
Christian Fischer · Natick, US
Brendan M. O'Boyle · Boston, US
David Joseph Guerin · Natick, US
Corey E. Bienstock · Natick, US
Christopher W. Boyce · Flemington, US
Matthew H. Daniels · Somerville, US
Danielle Falcone · Brookline, US
Ronald D. Ferguson · Scotch Plains, US
Salem Fevrier · Cranford, US
Xianhai Huang · Hackettstown, US
Kathryn Lipford · Boston, US
David L. Sloman · Brookline, US
Kevin J. Wilson · Boston, US
Wei Zhou · Scotch Plains, US
David J. Witter · Norfolk, US
Milana Maletic · Summit, US
Phieng Siliphaivanh · Newton, US

Key dates

Filing date	Oct 25, 2012
Grant date	May 5, 2015
Priority date	—
Expiry date	Oct 25, 2032

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07D519/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Disclosed are the ERK inhibitors of formula (1): and the pharmaceutically acceptable salts thereof. Also disclosed are methods of treating cancer using the compounds of formula (1).

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.